Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Atai Life Sciences And Beckley Psytech Announce Clinical Evidence Supporting Two-Dose Induction Of BPL-003 With Sustained Antidepressant Benefits

Author: Benzinga Newsdesk | September 23, 2025 06:05am

Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, which are sustained for up to 3 months
The second dose of BPL-003 led to further reductions in MADRS scores from baseline, indicating that this regimen has the potential to enhance the clinical response beyond what is observed with a single administration
Findings will be used alongside data from Beckley Psytech's Phase 2b study of BPL-003 and the soon to be reported Phase 2b open-label extension study to inform the Phase 3 clinical program

Posted In: ATAI